Viridian Therapeutics, Inc. (VRDN)
28.10
-0.01
(-0.04%)
USD |
NASDAQ |
Feb 19, 16:00
26.75
-1.35
(-4.80%)
After-Hours: 20:00
Viridian Therapeutics Research and Development Expense (Quarterly) : 86.15M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | 2.346M |
| ADMA Biologics, Inc. | 1.528M |
| Avantor, Inc. | -- |
| Immunovant, Inc. | 98.92M |
| Plus Therapeutics, Inc. | 2.436M |